4//SEC Filing
Hyep Ivan 4
Accession 0002034668-25-000004
CIK 0002023658other
Filed
Oct 7, 8:00 PM ET
Accepted
Oct 8, 5:33 PM ET
Size
19.2 KB
Accession
0002034668-25-000004
Insider Transaction Report
Form 4
Hyep Ivan
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-10-07$18.22/sh−18,244$332,386→ 145,355 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-08−5,627→ 122,999 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (5,627 underlying) - Sale
Common Stock
2025-10-08$18.21/sh−5,627$102,456→ 145,355 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-07−18,244→ 128,626 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (18,244 underlying) - Sale
Common Stock
2025-10-06$18.17/sh−6,514$118,356→ 145,355 total - Exercise/Conversion
Common Stock
2025-10-06$3.79/sh+6,514$24,687→ 151,869 total - Exercise/Conversion
Common Stock
2025-10-07$3.79/sh+18,244$69,141→ 163,599 total - Exercise/Conversion
Common Stock
2025-10-08$3.79/sh+5,627$21,325→ 150,982 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-06−6,514→ 146,870 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (6,514 underlying)
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F4]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
Documents
Issuer
Bicara Therapeutics Inc.
CIK 0002023658
Entity typeother
Related Parties
1- filerCIK 0002034668
Filing Metadata
- Form type
- 4
- Filed
- Oct 7, 8:00 PM ET
- Accepted
- Oct 8, 5:33 PM ET
- Size
- 19.2 KB